MILAN, Italy, Sept. 14 /PRNewswire/ -- Eurand today announced that an agreement has been signed with Recordati S.p.A. for the development of a modified-release formulation of lercanidipine (Zanidip(R)), Recordati’s original calcium channel blocker for the treatment of hypertension.
Under the feasibility agreement Eurand will apply its Diffucaps(TM) technology to the development of a new modified-release formulation of lercanidipine.
“Eurand’s consolidated formulation technology will allow us to develop a new and improved formulation of Zanidip(R)” -- said Dr. Avi Sartani, Director and Vice President of Research and Development at Recordati -- “and represents another step forward in the life cycle management of this important drug.”
“We are excited to be initiating this project with Recordati for the development of an enhanced formulation of this important product,” commented Eurand’s CEO, Gearoid Faherty “and look forward to a long and mutually rewarding collaboration between our two companies.”
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Spain, Switzerland and the United States.
Eurand is a specialty pharmaceuticals company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The Company specializes in bioavailability enhancement of poorly soluble drugs, utilizing its Biorise(R) platform, modified release and taste masking and is currently developing a pipeline of products based on its proprietary technologies. Eurand also works with many of the world’s leading pharmaceutical and biotechnology companies to develop enhanced forms of their existing products and development compounds. Eurand’s principal operating offices are located in Milan, Italy while Eurand’s US operating offices are in Vandalia, Ohio. The Company has research, development and manufacturing facilities in Italy, the United States and manufacturing facilities in France. For additional company information, please visit http://www.eurand.com/.
Eurand
CONTACT: Gearoid Faherty, CEO of Eurand, Italy - +39-02-954281,bizdev@eurand.com
Web site: http://www.eurand.com/
